Remgro Share Price JSE Resumes Uptrend Toward R200 on Strong Earnings and Dividend

Remgro Limited reported robust interim earnings growth, helping its share price recover and resume its broader upward trend.

Strong Interim Results Push Remgro Back Toward Long-Term Highs

Quick overview

  • Remgro Limited reported strong interim earnings growth for the six months ended December 31, 2025, with revenue rising to ZAR 27.1 billion.
  • Net income increased significantly to ZAR 5.17 billion, and headline earnings climbed 38.8% to ZAR 5.1 billion, driven by improved contributions from key investee companies.
  • The company declared an interim dividend of 173 cents per share, reflecting an 80% increase and strong cash generation.
  • Following the release of robust earnings, Remgro's share price rebounded, indicating renewed investor confidence and potential for continued growth.

Remgro Limited reported robust interim earnings growth, helping its share price recover and resume its broader upward trend.

Strong Interim Financial Performance

Remgro Limited delivered solid results for the six months ended December 31, 2025, reflecting improved operational performance across its portfolio. Revenue increased to ZAR 27.1 billion, up from ZAR 26.4 billion a year earlier.

Net income rose significantly to ZAR 5.17 billion, compared to ZAR 3.66 billion previously. Headline earnings climbed 38.8% to ZAR 5.1 billion, highlighting strong underlying profitability. This performance was largely driven by improved contributions from key investee companies and a recovery in CIVH.

Earnings Per Share Show Solid Growth

Profitability gains were also reflected at the per-share level:

  • Basic earnings per share (EPS): ZAR 9.30, up from ZAR 6.59
  • Diluted EPS: ZAR 9.22, up from ZAR 6.53

The strong EPS growth underscores the company’s ability to translate operational improvements into shareholder value.

Dividend Reflects Strong Cash Generation

Remgro declared an interim dividend of 173 cents per share, representing an 80% increase compared to the prior period.

The sharp rise in dividends signals robust cash generation at the holding company level and confidence in the sustainability of earnings.

Share Price Rebounds After Pullback

The stock experienced a period of weakness in late February, declining around 11% amid broader market volatility.

However, following the release of strong earnings, shares rebounded and are now moving back toward recent highs. The recovery suggests renewed investor confidence and a continuation of the longer-term uptrend.

Outlook: Momentum Builds Toward Long-Term Highs

With improved earnings, strong cash flow, and recovering portfolio performance, Remgro appears to be regaining momentum.

If current trends persist, the stock could continue advancing toward its longer-term highs, supported by consistent earnings growth and disciplined capital allocation.

Market Response and Share Price Rallies

The upbeat earnings guidance and subsequent strong results translated directly into market enthusiasm. Remgro’s share price surged from R179 at the start of the week to R187, after finding support and rebounding off the 200 daily SMA. On a yearly basis, the stock is up 16.4%, reflecting both recovery from late-2024 declines and confidence in the group’s long-term trajectory.

REMJ Chart Monthly – Heading to 2015 Highs

On the monthly timeframe, the share price has rebounded convincingly from its 200-month SMA and now trades closer to the historic highs of 2015 around R200. This resilience underscores investors’ renewed belief in Remgro’s diversified portfolio and earnings potential.

Key Earnings Highlights (H1 2026 – Six Months Ended 31 December 2025):
Key Drivers:
  • Investee Performance: Significant contributions from Mediclinic Holdings (R485 million), Rainbow Chicken (R280 million), and Heineken Beverages (R166 million).
  • CIVH Recovery: The CIVH-Vodacom transaction, which was completed in December 2025, contributed to a strong performance, including a special dividend of R2.66 billion.
  • Operational Challenges: Despite the growth, the company cited exposure to geopolitical volatility, specifically through Mediclinic’s operations in the UAE.
Outlook:
Remgro remains focused on disciplined capital allocation and growing its portfolio, noting that the company is well-positioned for future growth despite a volatile macroeconomic environment
ABOUT THE AUTHOR See More
Skerdian Meta
Lead Analyst
Skerdian Meta Lead Analyst. Skerdian is a professional Forex trader and a market analyst. He has been actively engaged in market analysis for the past 11 years. Before becoming our head analyst, Skerdian served as a trader and market analyst in Saxo Bank's local branch, Aksioner. Skerdian specialized in experimenting with developing models and hands-on trading. Skerdian has a masters degree in finance and investment.

Related Articles

HFM

HFM rest

Pu Prime

XM

Best Forex Brokers